Roxadustat in People With Heart Failure, Anaemia and Kidney Disease
Looks back at roxadustat's effects in adults with heart failure, anaemia and kidney disease.
Plain-language title generated from the registry record
Registry title: Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease
Key facts
- Where
- Nanjing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07268807, who can take part
Where in China
- Zhongda Hospital Southeast UniversityNanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhongda Hospital
- Trial code
- NCT07268807
- Record updated
- 8 December 2025
- Original description
Previous clinical observations of potential benefit from Roxadustat in this complex patient population prompted this investigation Therefore, the investigators designed this retrospective, observational study to thoroughly investigate the effects of Roxadustat on heart failure treatment and ventricular remodelling in this specific patient population, aiming to provide new insights for patients management.Read full original descriptionShow less
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease: A Single-Centre Retrospective Study
Previous clinical observations of potential benefit from Roxadustat in this complex patient population prompted this investigation Therefore, the investigators designed this retrospective, observational study to thoroughly investigate the effects of Roxadustat on heart failure treatment and ventricular remodelling in this specific patient population, aiming to provide new insights for patients management.
Inclusion: aged 18-85 years, regardless of gender; fulfilled the diagnostic criteria for heart failure and chronic kidney disease; haemoglobin level <130 g/L for men or <120 g/L for women at baseline; had regularly received Roxadustat for over one year; possessed complete clinical data, including information from pre-specified time points.
Exclusion: participation in a drug clinical trial within one year; comorbid myelodysplastic syndromes, multiple myeloma, hereditary hematologic diseases (e.g., thalassemia, sickle cell anaemia, pure red cell aplasia), hemosiderosis, hemochromatosis, or other disorders confirmed to cause anaemia due to erythrocyte destruction and/or abnormal hematopoietic function; bilateral nephrectomy, kidney transplantation within ≤6 months, or congenital kidney diseases (e.g., polycystic kidney disease); hypertrophic obstructive cardiomyopathy or congenital heart disease with right-to-left shunt; comorbid malignancy with an investigator-assessed life expectancy of less than 12 months; known allergy to the study drug (active ingredient or excipients); haemoglobin level ≤45 g/L on two or more blood tests, a history of major bleeding within one year, or a history of anaemia corrected by blood transfusion; pregnancy or lactation.